Rosiglitazone and cardiovascular risk [2]

New England Journal of Medicine

Volumn 357, Issue 9, 2007, Pages 937-940

  Bracken, Michael B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; HEART INFARCTION; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 34548320840     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc071602     Document Type: Letter

References (4)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. N Engl J Med 2007;356:2457-71. [Erratum, N Engl J Med 2007;357:100.]
2. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
3. Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions 4.2.6. (Accessed August 9, 2007, at http://www.cochrane.org/ resources/handbook/index.htm.)
4. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of metaanalytical methods with rare events. Stat Med 2007;26:53-77.